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Abstract
Background: The differentiated assessment of functional parameters besides morphological changes is essential for
the evaluation of prognosis in systemic immunoglobulin light chain (AL) amyloidosis.
Methods: Seventy-four subjects with AL amyloidosis and presence of late gadolinium enhancement (LGE) pattern
typical for cardiac amyloidosis were analyzed. Long axis strain (LAS) and myocardial contraction fraction (MCF), as
well as morphological and functional markers, were measured. The primary endpoint was death, while death and
heart transplantation served as a composite secondary endpoint.
Results: After a median follow-up of 41 months, 29 out of 74 patients died and 10 received a heart transplant. Left
ventricular (LV) functional parameters were reduced in patients, who met the composite endpoint (LV ejection
fraction 51% vs. 61%, LAS − 6.9% vs − 10%, GLS − 12% vs − 15% and MCF 42% vs. 69%; p < 0.001 for all). In
unadjusted univariate analysis, LAS (HR = 1.05, p < 0.001) and MCF (HR = 0.96, p < 0.001) were associated with
reduced transplant-free survival. Kaplan-Meier analyses showed a significantly lower event-free survival in patients
with reduced MCF. MCF and LAS performed best to identify high risk patients for secondary endpoint (Log-rank test
p < 0.001) in a combined model. Using sequential Cox regression analysis, the addition of LAS and MCF to LV ejection
fraction led to a significant increase in the predictive power of the model (χ2 (df = 1) = 28.2, p < 0.001).
Conclusions: LAS and MCF as routinely available and robust CMR-derived parameters predict outcome in LGE positive
AL amyloidosis. Patients with impaired LV function in combination with reduced LAS and MCF are at the highest risk
for death and heart transplantation.
Keywords: Immunoglobulin light chain amyloidosis, Cardiovascular magnetic resonance, Long axis strain, Myocardial
contraction fraction, Longitudinal function, Prognosis
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Introduction
Immunoglobulin light chain (AL) amyloidosis is the most
common type of systemic amyloidois. The incidence in
developed countries is described about 9–12 cases/million
inhabitant per year and autopsy studies suggest that the
incidence might even be higher [1–3]. AL amyloidosis is
characterized by the extracellular deposition of monoclo-
nal light chains as insoluble and aggregated amyloid fibrils
in various tissues, leading to progressive organ dysfunction
and death [4, 5]. Commonly affected organs include the
heart, kidneys, gastrointestinal tract, liver and the nervous
system. Cardiac involvement is described in up to 50% of
AL amyloidosis patients during the course of the disease
[6], and is the most important determinant of clinical out-
come [7]. The median survival in patients with heart fail-
ure symptoms is about 6 months [8–10]. For prediction of
outcome, especially the two biomarkers, N-terminale
natriuretic peptide (NT-proBNP) and cardiac Troponin-T
(cTNT) are established [11–13]. Based on these bio-
markers the widely used Mayo Clinic staging was devel-
oped for risk stratification of AL patients [11, 14].
Beside development of heart failure symptoms, amyloid-
osis may initially lead to apparent left ventricular (LV) wall
thickening mimicking left ventricular hypertrophy (LVH).
Cardiovascular magnetic resonance (CMR) imaging is
recommended as the diagnostic tool of choice in LVH as
it can help differentiate cardiac amyloidosis from other
potential causes of a cardiomyopathy (Fig. 1a) [15–17].
The presence of global diffuse myocardial late gadolinium
enhancement (LGE) pronounced in the subendocardial
layers is common in cardiac amyloidosis (Fig. 1b), and
has been associated with poor prognosis [18]. Besides
LGE, only few other markers, such as global longitu-
dinal strain (GLS), are available for risk stratification in
AL patients [19].
Therefore, this study aims to assess the novel CMR-
derived deriveparameters long axis strain (LAS) and
myocardial contraction fraction (MCF) for risk stratifica-
tion in patients with AL amyloidosis. Both parameters
have several important advantages. First, they can be de-
rived from every standard CMR examination without
the need for a dedicated post processing software. Sec-
ond, the assessment of LAS and MCF does not require
gadolinium contrast, which is relatively contraindicated
in patients with severe impaired renal function. Third,
unlike biomarkers, LAS and MCF are not influenced by
any organ dysfunction, which may exist in systemic
amyloidosis.
Methods
Study population and design
The goal of this study was to evaluate the prognostic
value of novel imaging parameter in biopsy-proven and
LGE-positive AL amyloidosis patients.
The study population consisted of consecutive patients
with AL amyloidosis, who received a CMR scan between
June 2005 and October 2014 at the University of Heidel-
berg as part of a standard institutional protocol for the
Fig. 1 Representative cardiovascular magnetic resonance (CMR) images of a) a patient with light chain (AL) amyloidosis demonstrating global left
ventricular (LV) wall hypertrophy, pericardial effusion and both-sided pleural effusions, b Late gadolinium enhancement (LGE) pronounced in the
subendocardial layers in cardiac amyloidosis (marked with a red line) and c) long axis strain (LAS) measurement
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evaluation of cardiomyopathies. CMR was performed in
all patients with AL amyloidosis in a clinically stable
condition.
Only patients with biopsy-proven AL amyloidosis
and LGE pattern characteristic for cardiac amyloidosis
were included in the analysis. Exclusion criteria were
contraindications for CMR including incompatible devices
such as cardiac pacemakers or implantable cardioverter
defibrillators (ICD) or other metallic implants, severe
claustrophobia, severe obesity preventing patient entrance
into the scanner bore, and pregnancy or lactation. Patients
with renal failure and an estimated glomerular filtration
rate (eGFR) < 30ml/min/1.73m2 were also excluded from
the analysis.
This single center study was approved by the local
Ethics Committee and in accordance with the Declar-
ation of Helsinki. The study population signed a written
informed consent for the retrospective post-hoc analysis
of their clinical routine data.
Adjudication of the diagnosis
In all patients, the diagnosis of systemic AL amyloidosis was
confirmed by biopsy and the cardiac involvement showed a
characteristically LGE pattern and LV morphology.
Diagnosis of AL amyloidosis was based on tissue depos-
ition of amyloid, the presence of a monoclonal gammopa-
thy by serum electrophoresis, immunofixation on serum
and urine, with free light chains, and conformation by
positive Congo red staining with birefringence under po-
larized light of any biopsy (periumbilical fat aspiration,
rectum, or target organ), positive immunohistology for
kappa or lambda in the biopsy, and on the exclusion of
hereditary forms of amyloidosis, if necessary.
Blood samples
Renal function, NT-proBNP, cTNT and the difference
between pathologic and nonpathologic serologic free
light chains (dFLC) were determined [20]. Because of
laboratory changes of the clinical routine from conven-
tional cTNT to high sensitivity cTNT (hs cTnT), a part
of study population has conventional cTNT (n = 34) the
other hs cTNT (n = 40). The samples for NT-proBNP
and cTNT were analyzed using the commercially available
sandwich immunoassay on a fully automated analyzer
(ELECSYS, Roche Diagnostics, Mannheim, Germany).
eGFR was calculated in each individual using the “Modi-
fied Diet in Renal Diseases” (MDRD) formula [21].
CMR protocol
All CMR scans were performed on a 1.5 T CMR system
(Achieva™, Philips Healthcare Best, The Netherlands)
using an institutional standard protocol. A 32-channel
phased-array cardiac coil was used. Cine images were ob-
tained using a breath-hold, segmented-k-space, balanced
steady-state free precession sequence with retrospective
electrocardiogram (ECG) gating in long axis views (2, 4
and 3 chamber) as well as in contiguous short axis slices
covering the entire LV and right ventricle (RV) from the
annulus of the atrioventricular valves to the apex, with 35
phases per cardiac cycle. The CMR imaging parameters
were: field-of-view (FOV) = 350 × 350mm2, repetition
time/echo time (TR/TE) = 2.8/1.4 ms, acquired voxel
size = 2.2 × 2.2 × 8mm3, flip angle (FA) = 60°, recon-
structed voxel size = 1.3 × 1.2 × 8mm3. Data were analyzed
by a single examiner blinded to the patient’s clinical status.
The analysis was performed on a commercially available
clinical workstation (IntelliSpace Portal (ISP) Version
7.0.1, Philips Healthcare). Results for LV volumes, LV ejec-
tion fraction (LVEF) and LV myocardial mass were derived
from short axis slices by tracing endocardial and epicardial
borders of the LV. Papillary muscles and trabeculations
were excluded from LV mass. LGE imaging acquisitions
were performed 10min after the administration of 0.2
mmol Gd-DTPA/kg body weight (Magnevist, Schering,
Germany). For selection of appropriate inversion time
(TI) gradient echo sequences were used to null myocardial
signal. The TI scout had the following parameters: TE 2.0
milliseconds, TR 3.4 milliseconds and flip angle 25°.
Three-dimensional LGE sequences were carried out dur-
ing breath-hold in expiration and using retrospective ECG
gating. The pattern of LGE was described as transmural if
LGE involved circumferential the complete subendocar-
dium through to the epicardium. The presentation of sub-
endocardial involvement was specified as subendocardial
LGE. The term patchy and focal LGE was used for de-
scription of any other LGE distribution, for example a
mid-wall, subepicardial or diffuse.
Assessment of long Axis strain (LAS) and myocardial
contraction fraction (MCF)
LAS is an image based functional marker that describes
longitudinal function. LAS is defined as the percentage
in longitudinal shortening of the LV between end-dia-
stole and end-systole (Fig. 1c). To calculate LAS we uti-
lized the strain formula:
LAS ¼ lsys−ldias
ldias
∙100 %½ 
MCF was calculated by dividing LV stroke volume (LV
end-diastolic volume - LV end-systolic volume) by LV
myocardial volume:
MCF ¼ LV Stroke volume mlð Þ
LV Myocardial Volume mlð Þ 100 %½ 
LV myocardial volume was defined as LV myocardial
mass divided by the mean density of myocardium, which
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is 1.05 g/ml. To achieve the index the result was multi-
plied by 100.
Both parameters have been validated for their diagnos-
tic and prognostic value in previous studies [22–25].
Assessment of longitudinal strain using feature tracking
imaging (FTI)
CMR myocardial global strain analyses were performed
using dedicated 2D CPA CMR Feature tracking software
(TomTec Imaging Systems, Munich, Germany). This
software algorithm has been validated previously in ex-
perimental and clinical studies [26–28]. The LV endocar-
dial borders of a 4-chamber view were used for the
calculation of the longitudinal strain and an automatic
tracking was performed throughout the complete car-
diac cycle. If the automatic tracking was incorrect, the
contours were manually adjusted. Measurements were
repeated three times and then averaged, resulting in the
mean segmental strains and GLS. The technique has
been described in detail recently [29].
Outcomes and follow-up
All-cause mortality was the primary study endpoint.
The combination of all-cause mortality and heart
transplantation (HTX) due to progressive disease was
defined as the secondary endpoint. Follow-up was ob-
tained by review of the patient’s hospital chart or
telephone interview with the patient or relatives. All
survivors completed the 2 years of follow-up. The
median follow up of surviving patients was 55 months
(43–66 months).
Statistics
Categorical variables are given as number and per-
centage, continuous parametric variables as mean ±
standard deviation (SD) and continuous non-paramet-
ric variables as median and interquartile range (IQR).
For the comparison of means between groups two-
tailed Student’s t-test was used and differences be-
tween nominal variables were assessed using the Fisher
exact test. Group differences of continuous non-paramet-
ric variables were tested using the nonparametric Mann-
Whitney U test. Proportions of categorical were compared
using Chi-squared test. Correlations were analysed using
Spearman’s rank correlation coefficient. Kaplan-Meier
curves were used to estimate the distribution of survival
as a function of the follow-up duration. Optimal cut-off
values were defined by Receiver operating characteristics
(ROC) and Youden’s J statistic. The association of clinical,
imaging and serological parameters with outcome was
evaluated by uni- and multivariate Cox proportional-
hazards regression models. Differences were considered
statistically significant at p < 0.05. All statistics were
calculated using MedCalc 15 (MedCalc™, Mariakerke,
Belgium).
Results
Baseline characteristics
Initially 94 patients with systemic AL amyloidosis were
included in the study. However, 20 patients, who re-
ceived chemotherapy before CMR was performed, were
excluded from the final analysis. Therefore, the total
study consists of 74 subjects.
Chemotherapy was administered 65 days (22–106
days) after CMR examination. 15 participants (20.3%)
received melphalan and dexamethasone, 16 (21.6%)
bortezomib and further 43 (58.1%) received other forms
and combinations of chemotherapy. The amount of
organ involvement was heterogenic (patient number:
organs involved: 16:1, 25:2, 20:3, 6:4 and 7:5).
During the follow-up period of 2 years, 29 patients
died, while 10 patients (13.5%) received a HTX. After
the follow-up period, 35 patients were alive without
HTX (47.3%), leaving 39 patients (52.7%), who
reached the combined endpoint of death or HTX.
Baseline characteristics including co-morbidities, la-
boratory data and CMR measurements are presented
in Table 1.
The age of all study participants was 59 ± 11 years and
50 (68%) subjects were male. Cardiovascular disease risk
factors were presented in both groups (alive vs. death/
HTX) without any significant difference (Table 1). Arterial
hypertension was the most common risk factor (35%).
Nearly half of the patients presented with dyspnea New-
York-Heart-Association (NYHA) class III (49%). The
number of patients with lambda light chains (n = 60,
81.1%) was higher than the one of kappa light chains (n =
14, 18.9%). The values of dFLC (108.9 ± 78 vs. 321.2 ±
197.3, p < 0.001) and NT-pro BNP were higher in pa-
tients, who reached the combined endpoint. In addition, a
high proportion of the total study population presented
positive values of cTNT (71.6%).
CMR measurements of LV end-systolic volume, LVEF,
mass as well as strain analysis demonstrated a significant
difference in patients who met the composite endpoint
(Table 1). Standard two-dimensional (2D) GLS was re-
duced in all AL patients (− 13.7 ± 5.5%) with a significant
difference in both groups of the secondary composite
endpoint (− 15.4 ± 5.9% vs. -12.2 ± 4.7%, p = 0.011). In
addition, the segmental longitudinal strain analysis dem-
onstrated normal longitudinal strain of the apical seg-
ments, while basal segment strain segments were
significantly reduced (longitudinal strain values of basal
segments: − 12.8 ± 10.7, midwall segments: − 17.2 ± 11.7
and apical segments: − 22.4 ± 11.1, p < 0.01). However,
the segmental analysis did not significantly differ be-
tween both groups (Table 1).
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Correlation analysis
There was an intermediate correlation between MCF and
LAS (Spearman’s coefficient of rank correlation/rho: − 0.72,
p < 0.0001). In addition, the correlations between the
CMR-derived parameters (MCF and LAS) and cardiac bio-
markers (NT-proBNP and cTNT) was weak to moderate
(Spearman’s coefficient of rank correlation/rho between: 1.
MCF and NT-proBNP − 0.6, p < 0.0001; 2. MCF and cTNT
− 0.41, p < 0.001; 3. LAS and NT-proBNP 0.59, p < 0.001;
4. LAS and cTNT 0.27, p = 0.006).
Survival analysis
In the unadjusted univariate analysis NYHA class, the
Karnofsky index, cardiac biomarkers and parameters of
myocardial morphology and function as assessed by
CMR were significantly associated with overall survival
Table 1 Demographics and cardiovascular magnetic resonance (CMR) data of patients with light-chain amyloidosis (n = 74), with
and without reaching the composite endpoints during the follow-up of 2 years
CMR Data All (n = 74) Transplant-free survivors
(n = 35)
Composite endpoint
(death or heart transplantation)
(n = 39)
p-Value (between transplant
free survivors and composite
endpoint)
Age (years) 58.5 ± 10.8 58.2 ± 9.8 58.7 ± 11.7 0.84
BMI (kg/m2) 25.9 ± 4.5 26.4 ± 4.8 25.5 ± 4.2 0.4
Male gender, n (%) 50 (67.6) 21 (60) 29 (74.4) 0.2
Cardiovascular risk factors, n (%)
Arterial hypertension 26 (35) 11 (31.4) 16 (41) 0.31
Dyslipidemia 10 (13.5) 6 (17.1) 4 (44) 0.45
Diabetes mellitus 7 (9.5) 5 (14.3) 2 (5.1) 0.27
Smoking 12 (16.2) 5 (14.3) 7 (17.9) 0.67
Family history of sudden cardiac death 4 (5.4) 1 (2.9) 3 (7.7) 0.4
Clinical data
NYHA class, n (%) 0.03
I 15 (20.3) 11 (31.4) 4 (10.2)
II 23 (31.1) 12 (34.3) 11 (28.2)
III 36 (48.6) 12 (34.3) 24 (61.5)
Karnofsky index 79.5 ± 11.5 84.6 ± 7.6 74.9 ± 12.5 < 0.001
Laboratory data
Lambda restricted pts. 60 (81.1) 26 (74.3) 34 (81.2) 0.3
Kappa restricted pts. 14 (18.9) 9 (25.7) 5 (12.8) 0.29
dFLC (mg/dL) 222.3 ± 110 108.9 ± 77.9 321.2 ± 197.3 < 0.001
MDRD (mL/min/1.73m2) 68.3 ± 24.7 71.1 ± 23.7 65.7 ± 25.9 0.36
Positive Troponin, n (%) 53 (71.6) 19 (54.3) 34 (87.2) 0.002
ln NT-pro BNP 7.6 ± 1.8 6.4 ± 1.9 8.4 ± 1.2 < 0.001
CMR Data
LAS (%) −8.4 ± 3.7 −10 ± 3.7 −6.9 ± 3.2 < 0.001
MCF (%) 54.9 ± 26.2 69.3 ± 27.5 42 ± 15.7 < 0.001
LVEDVI (ml/m2) 72.2 ± 18.7 72.6 ± 19.1 71.8 ± 18.6 0.89
LVESVI (ml/m2) 32.5 ± 14 28.8 ± 11.6 35.9 ± 15.2 0.03
LVEF (%) 55.6 ± 11.9 60.5 ± 11.5 51.2 ± 10.7 < 0.001
LVMI (g/m2) 84.8 ± 29 71.5 ± 20.2 96.8 ± 30.7 0.014
GLS (%) −13.7 ± 5.5 −15.4 ± 5.9 − 12.2 ± 4.7 0.011
Basal longitudinal strain (%) −12.8 ± 10.7 −14.3 ± 11.9 −11.5 ± 9.5 0.27
Midwall longitudinal strain (%) −17.2 ± 11.7 −18.3 ± 12.7 −16.2 ± 10.8 0.46
Apical longitudinal strain (%) −22.4 ± 11.1 −23.1 ± 12 −21.8 ± 10.2 0.63
Abbreviations: dFLC free light chain difference, GLS global longitudinal strain, LAS long axis strain, LVEDVI left ventricular end-diastolic volume index, LVESVI left
ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, MCF myocardial contraction fraction, NYHA New-York-
Heart-Association, NT – pro BNP N-terminale natriuretic peptide
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(Table 1). Especially, measurements of the LV function,
including LAS (Hazard ratio (HR) = 1.2, p < 0.001),
GLS (HR = 0.92, p = 0.04), LV mass index (LVMI) (HR =
1.02, p < 0.001), LV ejection fraction (LVEF) (HR =
0.97, p = 0.02) and MCF (HR = 0.96, p < 0.001) were all
associated with a reduced survival in patients with AL
amyloidosis (Table 2 and 3).
In a stepwise multivariate Cox regression model only
MCF and Karnofsky Index were independent predictors
for the primary endpoint (Table 4). While, MCF, LAS
and NT-proBNP remained independent predictors for
the composite endpoint (Table 5). Therefore, MCF alone
was associated with a reduced survival in both, primary
and composite, endpoints.
MCF featured the largest area under the curve (AUC =
0.81) based on the ROC curve analysis regarding the
secondary endpoint. The AUC for LAS was 0.75 and for
GLS was 0.65. A significant difference was found be-
tween the fields under the ROC curves for MCF and
GLS (p = 0.012, Fig. 2).
Risk stratification in AL amyloidosis
The Kaplan-Meier analyses for primary and for compos-
ite endpoint demonstrated a significantly reduced event-
free survival in patients with a LAS value above − 7%
and a MCF value below 56.6% (Log-rank test p < 0.001,
Fig. 3a and b). The combined predictor model including
MCF and LAS, could better risk stratify patients regard-
ing the primary and secondary endpoint (Fig. 4a and b).
Using a sequential Cox regression analysis for an im-
aging based predictor model, the addition of LAS to a
model including LVEF (χ2 (df = 1) = 16.3) led to a signifi-
cant increase in the predictive power (χ2 (df = 1) = 22.6,
p < 0.001). The addition of MCF to this model resulted
in a further significant increase in the predictive power
(χ2 (df = 1) = 28.2, p < 0.001) (Fig. 5).
Subgroup LGE analysis in AL amyloidosis
The complete study population presented a LGE distri-
bution characteristically for cardiac amyloidosis. How-
ever, the analysis of the exact distribution pattern was
not possible in the complete study population, which is
conditioned by the challenge in choosing the appropriate
TI. Therefore, only 70 of 74 (95%) LGE images were
Table 2 Univariate analysis of all patients (n = 74) for primary
endpoint (death)
Primary endpoint
Variable Hazard ratio 95% CI p-value
NYHA class 1.8 1.1–2.9 0.02
Karnofsky Index 0.94 0.92–0.97 < 0.001
dFLC (mg/dL) 1.0 0.99–1.01 0.27
Positive Troponin values 2.3 1.2–4.7 0.02
ln NT-pro BNP 2.8 0.98–8.1 0.06
LAS (%) 1.2 1.1–1.4 < 0.001
MCF (%) 0.96 0.94–0.98 < 0.001
LVESVI (ml/m2) 1.01 0.99–1.04 0.13
LVEF (%) 0.97 0.94–0.99 0.02
LVMI (g/m2) 1.02 1.01–1.03 < 0.001
GLS (%) 0.92 0.85–0.99 0.04
Abbreviations: dFLC free light chain difference, GLS global longitudinal strain,
LAS long axis strain, LVESVI left ventricular end-systolic volume index, LVEF left
ventricular ejection fraction, LVMI left ventricular mass index, MCF myocardial
contraction fraction, NYHA New-York-Heart-Association, NT-pro BNP N-
terminale natriuretic peptide
Table 3 Univariate analysis of all patients (n = 74) for composite
endpoint (death and heart transplantation)
Composite endpoint
Variable Hazard ratio 95% CI p-value
NYHA class. 1.9 1.2–3.0 0.006
Karnofsky Index 0.95 0.93–0.98 < 0.001
dFLC (mg/dL) 1.0 0.99–1.01 0.2
Positive Troponin values 2.5 1.3–4.6 0.005
ln NT-pro BNP 3.8 1.3–11 0.01
LAS (%) 1.23 1.1–1.4 < 0.001
MCF (%) 0.96 0.94–0.99 < 0.001
LVESVI (ml/m2) 1.04 1.02–1.04 0.006
LVEF (%) 0.95 0.92–0.97 < 0.001
LVMI (g/m2) 1.01 1.0–1.03 < 0.001
GLS (%) 0.91 0.85–0.97 0.005
Abbreviations: dFLC free light chain difference, GLS global longitudinal strain,
LAS long axis strain, LVEDVI left ventricular end-diastolic volume index, LVESVI
left ventricular end-systolic volume index, LVEF left ventricular ejection
fraction, LV MI left ventricular mass index, MCF myocardial contraction fraction,
NYHA New-York-Heart-Association, NT – pro BNP N-terminale
natriuretic peptide
Table 4 Multivariate proportional-hazard model for primary
endpoint (death)
Endpoint
Variable Hazard ratio 95% CI p-value
MCF 0.97 0.96–0.99 0.002
Karnofsky Index 0.96 0.93–0.99 0.006
Abbreviations: MCF myocardial contraction fraction
Table 5 Multivariate proportional-hazard model for composite
endpoint (death and heart transplantation)
Endpoint
Variable Hazard ratio 95% CI p-value
MCF 0.96 3.6–32.4 < 0.001
LAS 1.05 0.94–0.98 < 0.001
ln NT-pro BNP 5.2 1.8–15,3 0.003
Abbreviations: LAS long axis strain, MCF myocardial contraction fraction, NT –
pro BNP N-terminale natriuretic peptide
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available for a reliable analysis. Our analysis demonstrated a
trend of higher mortality rates in patients presenting trans-
mural LGE. However, we found no significant difference
between the LGE pattern and the endpoint (Additional
file 1: Table S6, Additional file 2: Figure S6). Furthermore,
there was no significant difference between the mean values
of the CMR parameter in the different LGE groups (group
1: subendocardial LGE, n = 26 (37.1%), group 2: transmural
LGE, n = 25 (35.7%) and group 3: patchy and focal LGE,
n = 19 (27.1 Additional file 1: Table S7).
Discussion
To our knowledge, this is the first study assessing two
novel CMR-derived imaging parameters for risk predic-
tion in patients with systemic AL amyloidosis, who
already presented with cardiac involvement and the
presence of LGE. The determination of LAS and MCF
can further risk stratify these subjects. AL amyloidosis
patients with a restricted LV function combined with re-
duced LAS (> − 7%) and MCF (≤ 52.6%) values were at
greatest risk for death.
Cardiac involvement of AL amyloidosis is a major de-
terminant of treatment options and prognosis. Early
identification of high-risk patients may lead to begin of
intensive therapeutic strategies with better survival.
Cardiac serum biomarkers NT-proBNP and cTNT are
currently used in clinical routine for estimation of the
prognosis in patients with cardiac involvement. Previous
studies have shown a significant correlation between
LGE extent on CMR and biomarkers of myocardial in-
jury in patients with acute viral myocarditis [30].
CMR is currently the diagnostic tool of choice for
identification of cardiac amyloidosis. Additionally, it has
been shown, that presence of LGE in patients with sys-
temic amyloidosis is associated with mortality [31, 32].
However, myocardial LGE, pronounced in the subendo-
cardial layers, is common in cardiac amyloidosis and
thus, further parameters are of great clinical interest.
Furthermore, the application of contrast agents is fre-
quently contraindicated, due to reduced renal function.
In addition, our subgroup analysis could not show any
difference regarding outcome and LGE pattern. There-
fore, there is a need for additional parameters, such as
LAS and MCF, which can contribute to the identification
of very high-risk amyloidosis patients.
Previous studies have already shown that LV longitu-
dinal function may be a marker for early diagnosis and
outcome in cardiac diseases of various etiologies [33–35].
Especially, the assessment of LV longitudinal function by
strain using tissue Doppler echocardiography has been de-
scribed to identify early impairments of LV function in AL
amyloidosis [36, 37]. In addition, the longitudinal function
by strain analysis was associated with poor prognosis and
outperformed standard echocardiographic parameters
Fig. 2 Receiver operating characteristic (ROC) curves for myocardial contraction fraction (MCF), long axis strain (LAS) and global longitudinal strain
(GLS) in AL amyloidosis patients for the combined the composite endpoint (death and heart transplantation)
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suggesting that strain imaging could serve as a new tool to
identify high risk subjects [19, 38, 39]. Our study results
are in agreement with previous data. First, longitudinal
strain derived from cine CMR imaging demonstrated the
specific amyloidosis pattern with normal apical and re-
duced strain values of the basal segments, and second,
impaired GLS was associated with reduced outcome.
However, in a stepwise multivariate Cox regression model
LAS and MCF outperformed GLS [40].
CMR-derived LAS has been shown to be a simple and
rapidly assessable parameter representing global LV lon-
gitudinal function without the necessity of additional
post-processing software tools [24]. The major advan-
tages of LAS are its independence of dedicated software
and its very good intra- and interobserver variability
[24]. The diagnostic and prognostic value of LAS was
evaluated in non-ischemic cardiomyopathies (NICM)
[23, 25]. Previous analysis demonstrated not only a sig-
nificantly better performance of LAS than LVEF and mi-
tral annular plane systolic excursion (MAPSE) in
discriminating controls from NIDCM, but also a signifi-
cantly higher rate of cardiac events in NICM patients
with reduced LAS values, independent of the presence
of LGE [25]. Assessment of longitudinal function with
LAS offered incremental information for the prediction
of cardiac events in NICM and improved risk stratifica-
tion beyond established CMR parameters such as LVEF
and the presence of myocardial fibrosis. These results
Fig. 3 a) Kaplan-Meier estimates of the time to events by myocardial contraction fraction (MCF) optimized cut-off 56.6% for primary endpoint
(death) and b) for the composite endpoint (death and heart transplantation)
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were further confirmed in a recent publication on LAS
in NICM [23]. The current analysis could demonstrate
that CMR-derived LAS may also serve as reliable prog-
nostic marker in other cardiomyopathies, who are
known of reduced LV longitudinal contractility. In a
further study Doesch et al., showed a reduced LV longi-
tudinal shortening in hypertrophic cardiomyopathy
(HCM) patients measured by CMR-assessed MAPSE
compared to healthy controls [41].
MCF is a quantitative parameter representing a volu-
metric index of fractional contraction of the myocar-
dium. MCF is calculated as a ratio between LV stroke
volume and the LV myocardial volume. In LVH
independent of its etiology, a decrease in MCF indicates
an abnormal myocardial function, although LVEF may
remain normal even in advanced stages because of the
progressive reduction in ventricular capacitance. There-
fore, measurement of LVEF alone gives an incomplete
representation of the complex process of dysfunction es-
pecially in hypertrophied hearts. In a previous study we
could demonstrate that CMR-derived MCF has an excel-
lent diagnostic accuracy discriminate between patients
with AL amyloidosis from patients with other forms of
LVH [22]. We could define cut-off value for MCF of <
50%, which allowed to identify patients with a high
probability for cardiac amyloidosis. The prognostic value
Fig. 4 Kaplan-Meier estimates of the time to events by myocardial contraction fraction (MCF) and longitudinal axis strain (LAS). Presented a) for
primary endpoint (death) and b) for the composite endpoint (death and heart transplantation)
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of MCF in patients with cardiac amyloidosis (34 AL and
32 ATTR subjects) was studied by Tendler et al. [42].
The authors reported a superiority of MCF to LVEF in
predicting survival of patients with AL amyloidosis.
However, in this study MCF was assessed from 2D echo-
cardiography data, which are known for their limited ac-
curacy and reproducibility, especially when compared to
CMR as the accepted “gold standard” of LV mass mea-
surements [43]. Even the more recent approaches using
3D echocardiography show only limited performance
compared to CMR, suffering from substantial variability
and underestimation [16, 44]. Therefore, we assume that
MCF derived from CMR images is more accurate and
reproducible.
The present study has some limitations. First, it is a
retrospective analysis. Second, because of two different
Troponin essays (conventional and high-sensitivity) in
our institution during the study period, it was only pos-
sible to divide between troponin positive and negative
participants. Therefore, an assessment regarding Tropo-
nin values and outcome was not possible. Finally, be-
cause of a long period of data collection beginning from
2005, this study does not provide any T1 mapping
information.
Conclusions
In conclusion, LAS and MCF are easily available and ro-
bust CMR-derived parameters which predict outcome in
LGE-positive AL amyloidosis patients. Among these, pa-
tients with reduced LAS and MCF fraction are at highest
risk for death and HTX.
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